| abstract |
The present invention generally relates to 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazine-1-yl)-benzene amino]-pyrimidin-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or containing 3-(2,6-dichloro-3,5-dimethoxy-benzene base)-1-{6-[4-(4-ethyl-piperazine-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt thereof Or a pharmaceutical composition of a solvate for the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemia Sexual rickets (ARHR), tumor-derived osteomalacia, post-renal transplantation hypophosphatemia, epidermal nevus syndrome, skeletal dysplasia, or multiple fibrous dystrophy. |